The FDA Just Killed the Worst Wait in Medicine

How RAPID Actually Works

The core innovation is simple: get CMS involved before anyone applies for approval, not after.

Under RAPID, CMS joins the FDA's Breakthrough Devices Program engagements with manufacturers during the design phase of pivotal clinical trials. These are called Investigational Device Exemption (IDE) studies, the big trials that generate the evidence for FDA authorization. By sitting at the same table early, CMS can ensure those trials collect the clinical outcomes Medicare cares about. No duplicative studies. No evidence gaps. No surprises.

Then comes the real kicker: on the same day the FDA grants market authorization, CMS issues a proposed National Coverage Determination. A 30-day public comment period follows, and coverage can be finalized within 60 to 90 days of FDA approval. CMS Deputy Administrator John Brooks confirmed that timeline, saying the pathway enables coverage "within 60 to 90 days of FDA approval across Medicare."

Compare that to the standard NCD process, which typically takes a year or more. RAPID doesn't just shave off time; it fundamentally restructures the sequence.

Who Gets In?

Eligibility requires a few boxes to be checked. Devices must have FDA Breakthrough Device designation and address unmet medical needs for Medicare beneficiaries. Class III devices (the highest-risk category, think implantable hearts and neural stimulators) qualify regardless of other program participation. Class II devices need to be enrolled in the FDA's Total Product Life Cycle Advisory Program, known as TAP.

All candidates must be part of an IDE study that enrolls Medicare beneficiaries and evaluates clinical health outcomes agreed upon by both agencies.

The scale here matters. A senior CMS official said approximately 40 devices currently qualify, with 20 more potentially eligible. That's a massive expansion compared to TCET's five-per-year cap. The pathway has no device limit at all.

Why Medtech Is Cautiously Thrilled

Industry reaction has been positive but measured. AdvaMed CEO Scott Whitaker called RAPID a "positive step" for patient access while stressing the need for "meaningful timelines, accountability, and effective management" to realize its benefits. That caveat is worth noting. The graveyard of failed FDA-CMS coordination programs is well populated, and execution will determine whether RAPID lives up to its name.

Analysts at Orrick highlighted several downstream effects: reduced disparities compared to variable local coverage decisions, stronger investment incentives for medtech companies, and a more predictable commercialization timeline that could effectively halve post-approval uncertainty.

The Bigger Picture for Medtech Investors

For medtech companies developing breakthrough devices, the calculus just shifted. Historically, investors had to price in years of reimbursement uncertainty on top of the already grueling regulatory process. A device could be brilliant, FDA-approved, and commercially dead because Medicare wouldn't pay for it.

RAPID, if it delivers on its promise, shrinks the commercialization timeline dramatically. That means faster revenue, shorter cash burn runways, and a stronger case for venture and public market funding. The devices in or near eligibility represent a meaningful chunk of the medtech innovation pipeline.

A procedural notice is expected soon in the Federal Register, followed by a 60-day public comment period. The pathway takes effect upon publication of the final notice. Meanwhile, TCET has been paused for new candidates during implementation.

The medical device industry has been burned before by promises of streamlined coverage. But RAPID's structural approach (embedding CMS in trial design rather than bolting coverage review onto the back end) addresses the root cause of previous failures. It's not just a faster lane; it's a fundamentally different road.

Now comes the hard part: proving it actually works at scale.

The $400M Bet That AI Can Design Better Drugs Than Humans

Generate Biomedicines just raised $400 million in the largest biotech IPO since 2024, betting that AI can design better drugs than humans. With a Phase 3 asthma program, a generative biology platform, and the Moderna-incubator Flagship Pioneering behind it, this is the biggest test yet of whether AI drug design can survive public markets.